Literature DB >> 24637214

Discovery of N-substituted 3-arylisoquinolone derivatives as antitumor agents originating from O-substituted 3-arylisoquinolines via [2,3] or [3,3] rearrangement.

Bo Li1, Gaihong Wang2, Zhijian Xu2, Yong Zhang2, Xiangui Huang3, Bubing Zeng3, Kaixian Chen2, Jiye Shi4, Heyao Wang5, Weiliang Zhu6.   

Abstract

The present study discovers multiple N-substituted 3-arylisoquinolone derivatives as antitumor agents originating from O-substituted 3-arylisoquinolines via [2,3] or [3,3] rearrangement. The current [2,3] rearrangement of epoxy or acetal O-substituents converting to diol or alcohol N-substituents can be promoted by silica gel or by diluted hydrochloric acid, which is distinct from previously reported [2,3] rearrangements. Some of the derivatives displayed comparable or even stronger cytotoxicity than sorafenib and vemurafenib on HCT116 colon carcinoma and A375 melanoma cell lines. Therefore, the rearrangement via intramolecular carbon-oxygen bond cleavage and carbon-nitrogen bond formation should be a useful approach for developing novel anticancer drugs derived from isoquinolones.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  3-Arylisoquinolone; Antitumor; [2,3] rearrangement; [3,3] rearrangement

Mesh:

Substances:

Year:  2014        PMID: 24637214     DOI: 10.1016/j.ejmech.2014.03.008

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

1.  Regioselectivity and Mechanism of Synthesizing N-Substituted 2-Pyridones and 2-Substituted Pyridines via Metal-Free C-O and C-N Bond-Cleaving of Oxazoline[3,2-a]pyridiniums.

Authors:  Bo Li; Susu Xue; Yang Yang; Jia Feng; Peng Liu; Yong Zhang; Jianming Zhu; Zhijian Xu; Adrian Hall; Bo Zhao; Jiye Shi; Weiliang Zhu
Journal:  Sci Rep       Date:  2017-01-25       Impact factor: 4.379

Review 2.  Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system.

Authors:  Kun Zou; Zhao Li; Yong Zhang; Hao-Yue Zhang; Bo Li; Wei-Liang Zhu; Ji-Ye Shi; Qi Jia; Yi-Ming Li
Journal:  Acta Pharmacol Sin       Date:  2016-12-05       Impact factor: 6.150

3.  Discovery of dihydrooxazolo[2,3-a]isoquinoliniums as highly specific inhibitors of hCE2.

Authors:  Lixia Ding; Lu Wang; Kun Zou; Bo Li; Yunqing Song; Qihua Zhang; Yitian Zhao; Zhijian Xu; Guangbo Ge; Bo Zhao; Weiliang Zhu
Journal:  RSC Adv       Date:  2019-11-04       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.